Researchers are increasingly investigating retatrutide, a novel drug from Eli Lilly, as a potential advance in weight management. Different than many earlier approaches, retatrutide is a double -action receptor targeting equally GLP-1 and GIP, hormones that impact hunger and blood glucose balance… Read More